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A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of excep-
tional magnitude and breadth. A detailed analysis of the critical epitopes targeted by broadly neutralizing
antibodies should help to define optimal targets for vaccine design. HIV-1-infected subjects with potent
cross-reactive serum neutralizing antibodies were identified by assaying sera from 308 subjects against a
multiclade panel of 12 “tier 2” viruses (4 each of subtypes A, B, and C). Various neutralizing epitope
specificities were determined for the top 9 neutralizers, including clade A-, clade B-, clade C-, and clade
A/C-infected donors, by using a comprehensive set of assays. In some subjects, neutralization breadth was
mediated by two or more antibody specificities. Although antibodies to the gp41 membrane-proximal external
region (MPER) were identified in some subjects, the subjects with the greatest neutralization breadth targeted
gp120 epitopes, including the CD4 binding site, a glycan-containing quaternary epitope formed by the V2 and
V3 loops, or an outer domain epitope containing a glycan at residue N332. The broadly reactive HIV-1
neutralization observed in some subjects is mediated by antibodies targeting several conserved regions on the
HIV-1 envelope glycoprotein.
Broadly neutralizing antibodies (bnAbs) protect nonhuman
primates from experimental simian-human immunodeficiency
virus (SHIV) challenge (46–48, 61, 64, 81, 108) and are widely
expected to be a key component of protective immunity con-
ferred by an effective human immunodeficiency virus type 1
(HIV-1) vaccine (63). HIV-1 neutralization depends on the
ability of Abs to recognize native envelope glycoprotein (Env)
spikes, which consist of three surface gp120 subunits noncova-
lently linked to three membrane-spanning gp41 subunits (32,
70, 91). These spikes are compact structures protected by a
heavy glycan shield that disfavors nAb recognition. Not all nAb
epitopes are shielded, and in fact, the extent of shielding differs
considerably among strains. Thus, some viruses are highly sen-
sitive to neutralization by heterologous sera from HIV-1-in-
fected individuals and are classified as having a tier 1 neutral-
ization phenotype. However, most circulating strains are
considerably less sensitive to heterologous neutralization and
are classified as having a tier 2 phenotype (63).
A potent autologous nAb response against the early infecting
virus is generally seen within the first year of HIV-1 infection (62,
83, 104, 113). Longitudinal studies have revealed that the virus
and the host nAb response continually evolve (11, 73, 83, 86, 113).
After several years of infection, an estimated 10 to 30% of indi-
viduals develop bnAb responses (4, 7, 28, 52, 57, 66, 72, 88, 89).
Although these extraordinary responses have little impact in the
setting of established infection, they could have a major impact on
transmission if they could be induced by vaccines prior to virus
exposure. Thus, the epitopes and biological processes that give
rise to these exceptional bnAb responses are of considerable
interest for rational vaccine design (114).
Until recently, only 4 monoclonal Abs (MAbs) (2G12, b12,
2F5, and 4E10), all from HIV-1 clade B-infected individuals, were
known to potently neutralize genetically diverse isolates of HIV-1
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(8, 13, 75, 107, 119). MAb 2G12 recognizes a tight cluster of
glycans on the gp120 silent domain (14, 87, 93, 107). MAb b12
binds an epitope that overlaps the CD4 binding site (CD4bs) of
gp120 (13). MAbs 2F5 and 4E10 (75, 119) recognize adjacent
epitopes in the membrane-proximal external region (MPER) of
gp41. Three of these MAbs (b12, 2G12, and 2F5) exhibit limited
breadth and/or potency against non-clade B viruses, which ac-
count for the majority of infections worldwide (13). MAb 4E10
neutralizes more broadly, albeit usually at a lower magnitude.
Other MAbs, including those directed to the V3 loop, usually
exhibit a more limited profile of neutralization (51, 80), while
MAbs directed to CD4-induced epitopes usually fail to neutralize
tier 2 viruses altogether (8, 53, 115).
To date, vaccine immunogens targeting these MAb epitopes
have not succeeded in eliciting bnAbs (42, 69, 82, 92). Conse-
quently, there has been a resurgence of interest in isolating
new bnMAbs, particularly from non-clade B-infected individ-
uals, in the hope that these new epitopes will be more amena-
ble to vaccine development (9, 12, 16, 18, 31, 95). Several new
MAbs, most notably VRC01, VRC02, VRC03, PG9, PG16,
and HJ16 (18, 111, 114, 118), each of which possesses potent
activity against multiple genetic subtypes of the virus, have
been identified.
These new MAbs were derived from donors of diverse geo-
graphic backgrounds infected with one of three different
HIV-1 subtypes: A (MAbs PG9 and PG16), B (VRC01,
VRC02, and VRC03), and C (HJ16). This emphasizes the
importance of including globally diverse HIV-1-infected donor
material in bnAb epitope discovery efforts (76, 102). MAbs
VRC01 and HJ16 recognize epitopes that overlap the CD4
binding site (18, 114), while PG9 and PG16 recognize novel
quaternary epitopes involving the V1V2 and V3 loops of gp120
(27, 111). Mutations that remove sequons at positions N156
and N160 in the V2 loop eliminate the binding of PG9 and
PG16, as does enzymatic deglycosylation, suggesting that gly-
cans are involved in these quaternary epitopes. Soluble CD4
(sCD4) ablates the ability of the latter two MAbs to bind
trimers, suggesting that the conformational changes alter the
quaternary epitope. These V2-V3 epitopes were somewhat
surprising, considering that until recently, these loops were
thought to protect underlying conserved epitopes and were
considered too variable to be targets of broad neutralization.
These findings suggest that despite the variability of the V-
loops, conserved elements that can be targets of bnAb re-
sponses do exist.
Various technologies have been used to identify the epitopes
of bnAbs (reviewed in references 1, 4, 5, 7, 21, 24–26, 37,
39–41, 57, 89, 101, and 117). An analysis of serum samples
from approximately 200 individuals chronically infected with
HIV-1 revealed that about one-third exhibit low titers of
MPER nAbs, as detected by a sensitive HIV-2/HIV-1 MPER
chimera assay in which the MPER is spontaneously exposed
(3). However, in all but exceptional cases, these MPER nAbs
do not neutralize circulating strains of HIV-1. In most cases,
MPER nAbs were ascribed to 4E10-like epitopes, but 2F5-like
nAbs have also been reported in rare cases (7, 39, 41, 89, 101).
Some studies suggest that bnAbs in chronic HIV-1 infection
may be oligoclonal (2, 6, 23, 43, 95, 111). Indeed, recent work
suggests that the responses are limited in specificity, often
resembling PG9 and PG16 (111), are restricted in their IgG
heavy and light chain usage, and require extensive somatic
mutation (111). Furthermore, the observation that MAbs PG9
and PG16 largely recapitulate the neutralizing activity of the
donor plasma provides evidence that broad neutralization can
occur in some cases via a single specificity or multiple overlap-
ping specificities (111). An overarching question from these
studies concerns the number of nAb specificities that typically
mediate broad plasma neutralization (72, 90, 95, 112). Here, to
gain more insights into the frequency and titer of existing bnAb
specificities and possibly to identify new bnAb targets, we an-
alyzed the specificities of plasma samples from 9 HIV-1-in-
fected subjects who exhibited high-titer bnAbs. Distinct bnAb
specificities were present in the plasma from each subject, and
in some cases, more than one specificity contributed to neu-
tralization breadth.
MATERIALS AND METHODS
Chronically HIV-1 infected subjects. A total of 308 subjects chronically in-
fected with HIV-1 strains of clade A, B, or C were enrolled in the Center for
HIV/AIDS Vaccine Immunology cohort CHAVI 001 or CHAVI 008, and plasma
and serum samples (and, in some cases, purified IgG from cervical lavage [CVL])
were examined for antibody specificities and neutralizing activity. Donor enroll-
ment was based on standard clinical diagnosis of HIV-1 infection, at which time
subjects were all antiretroviral naïve. The donors were enrolled at clinical sites in
Tanzania, South Africa, Malawi, and the United Kingdom. This study was ap-
proved by the institutional review boards at each of the participating institutions
where samples were received or processed for end user analysis.
MAbs and sCD4. A panel of HIV-1 Env-specific MAbs (b12, VRC01, and
VRC03, directed to epitopes overlapping the CD4bs of gp120 [13, 114]; 2G12,
directed to a unique glycan-dependent epitope on gp120 [87, 93]; E51, directed
to a CD4-inducible [CD4i] epitope on gp120 [115]; 447-52D, F425, F2A3, and
39F, directed to the gp120 V3 loop [21, 80, 96, 99]; 2F5, Z13e1, and 4E10,
directed to the gp41 MPER [77, 120]; and PG9 and PG16, which recognize
quaternary epitopes involving the V1, V2, and V3 loops [111]) were utilized as
positive controls. Recombinant soluble CD4 (sCD4) consisting of all of the 4
outer domains was purchased from Progenics Pharmaceuticals (Tarrytown, NY).
HIV-1, HIV-2, and SIV isolates and pseudoviruses. The molecularly cloned
Env-pseudotyped viruses used for neutralization and mapping experiments were
produced by cotransfection of 293T cells with an Env-expressing plasmid and one
of two Env-deficient HIV-1 genomic backbone plasmids: pNL-LucR-E (for CF2
neutralization assays) or pSG3Env (for TZM-bl neutralization assays) (5, 55,
56). Env plasmids included subtype B and C tier 2 reference strains (55, 56) and
other strains described previously (5, 57, 97, 98). SHIV-89.6P and SHIV-
SF162P3 were uncloned live viruses grown in human peripheral blood mononu-
clear cells (PBMCs) (44). A series of point mutants was generated in the JR-FL
SOS, ConC, and CAP45.G3 Env plasmids. Plasmids expressing tier 1 Envs
SF162.LS and MW965.26 (15) were obtained from L. Stamatatos (Seattle Bio-
medical Research Institute) (103) and the NIH AIDS Reference and Reagent
Program (originally provided by B. Hahn) (33), respectively. Chimeric HIV-2
Envs containing various segments of the HIV-1 MPER were constructed from a
parental HIV-2/7312A plasmid (3, 39). The SIVmac239CS.23 Env plasmid was
subcloned from an animal challenge stock of molecularly cloned SIVmac239/
nef-open provided by R. Desrosiers (New England Primate Center).
HIV-1 Env IgG subclass binding antibody assay. IgG subclasses were deter-
mined by a custom HIV-1 Luminex assay with modifications for specific IgG
subclasses (105). Briefly, a total of 5  106 carboxylated fluorescent beads
(Luminex Corp., Austin, TX) were covalently coupled to 25 g of one of the
purified HIV antigens and were incubated with plasma or CVL samples. HIV-
specific antibody isotypes were detected with goat anti-human IgA (Jackson
ImmunoResearch, West Grove, PA), mouse anti-human IgG1 (BD Pharmin-
gen), mouse anti-human IgG2 (Southern Biotech), mouse anti-human IgG3
(Calbiochem), or mouse anti-human IgG4 (BD Pharmingen) conjugated to bi-
otin, at 4 g/ml, followed by washing and incubation with streptavidin-phyco-
erythrin (PE) (BD Pharmingen). Beads were then washed and acquired on a
Bio-Plex instrument (Bio-Rad, Hercules, CA). An HIV-1 plasma titration was
utilized as a positive control in every assay. Background values (beads in the
absence of the detection antibody) and normal human plasma were utilized as
negative controls. IgG1 to IgG4 equivalents were determined by titrating purified
IgG1 to IgG4 human myeloma proteins (Sigma) on beads coupled to purified
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anti-human IgG1 to IgG4 antibodies, detecting with goat-anti human  chain
(Southern Biotech) conjugated to biotin, washing, and incubating with strepta-
vidin-PE (BD Pharmingen). Binding antibody concentration (g/ml) equivalents
were calculated using a 4-parameter logistic (4PL) curve analysis.
Peptide array. Purified IgG was examined by a peptide microarray using an
Env peptide library containing 15-mer peptides, overlapping by 12 amino acids,
that cover the full length of the consensus HIV-1 Env gp160 sequences for
subtypes A, B, C, and D, group M, circulating recombinant form 1 (CRF 1), and
CRF 2 (designed by B. Korber, Los Alamos National Laboratory). The peptides
were printed onto 3D-Epoxy glass slides (PolyAn GmbH, Germany) by JPT
Peptide Technologies GmbH (Germany) and were analyzed with a GenePix
4000B scanner. Samples were hybridized to the library using a Tecan HS4000
hybridization workstation, followed by incubation with DyLight 649-labeled goat
anti-human IgG. Fluorescence intensity was measured using a GenePix 4000B
scanner and was analyzed with GenePix software.
Autoantibodies. Antibodies reactive to SSA/Ro, SS-B/La, Sm, ribonucleopro-
tein (RNP), Jo-1, double-stranded DNA (dsDNA), centromer B, and histone
were measured by the FDA-approved AtheNA MultiLyte ANA II test kit from
Zeus Scientific, Inc., according to the manufacturer’s instructions (45).
Neutralization assays. Neutralization was assessed in either TZM-bl or CF2
target cells. The single-cycle TZM-bl neutralization assay was used as described
previously (55). To determine the neutralizing IC50 (dilution inhibiting 50% of
virus activity) of plasma, serially diluted heat-inactivated plasma or MAb was
incubated with virus, and the neutralization dose-response curves were fit by
nonlinear regression using a 4-parameter Hill slope equation. In some cases,
plasma and mucosal IgG were purified for neutralization assays using protein G
columns (MultiTrap plates; GE, Inc.).
The stage of HIV-1 entry inhibition targeted by nAbs was determined by using
canine CF2 cell lines in standard and post-CD4/CCR5 assay formats as described
previously (5, 21). Briefly, in the standard format, the virus was incubated with
graded dilutions of the Ab for 1 h at 37°C. The mixture was added to CF2 cells,
spinoculated, and incubated for 2 h at 37°C, after which time the medium was
changed. After 3 days of culture, luciferase activity was measured. Neutralization
that occurred post-CD4/CCR5 binding was measured by using mutant particles
containing a disulfide bond (SOS) between gp120 and gp41 that blocks fusion (1,
5). Particles were allowed to attach to target cells for 2 h, after which time
unbound particles were removed by washing, and graded concentrations of Abs
were added for 1 h. Infection was activated by using 5 mM dithiothreitol (DTT)
for 10 min to reduce the gp120–gp41 disulfide bond, allowing infection to pro-
ceed. When neutralization was assessed against Env point mutant viruses for
mapping experiments, plasma samples were titrated in 2-fold dilutions against
both the parent and the mutant in duplicate at least twice. A positive knockdown
of neutralization was recorded if there was at least a 2-fold drop in the neutral-
izing titer. Similarly, enhancement was recorded if there was at least a 2-fold
increase in the titer. A murine leukemia virus (MLV)-enveloped pseudovirus was
used as a negative control in assays to confirm the absence of antiretroviral drugs,
which can score positive in the assays and be mistaken for nAbs.
Plasma fractionation using paramagnetic-bead-immobilized gp120 and
MPER peptides. Plasma fractionation by use of paramagnetic-bead-immobilized
gp120 has been described previously (37, 41, 58). The depletion of anti-gp120
(ConC) antibodies was evaluated by an enzyme-linked immunosorbent assay
(ELISA) as described elsewhere (58). Similarly, plasma was depleted of anti-
MPER antibodies by using streptavidin-coated magnetic beads coated with a
biotinylated linear MPER peptide (the MPR.03 peptide [KKKNEQELLELDK
WASLWNWFDITNWLWYIRKKK-biotin-NH2]) as described previously (37).
The percentage of gp120-directed activity was calculated as [(a  b)/a]  100,
and CD4bs activity as a percentage of total neutralization was calculated as [(c 
b)/a]  100, where a stands for adsorptions against a blank, b stands for adsorp-
tions against wild-type gp120, and c stands for adsorptions against the gp120
D368R mutant.
Native PAGE. Blue native polyacrylamide gel electrophoresis (BN-PAGE)
band shifts were used to analyze Ab binding to native, virion-derived Env trimers
as described previously (19–21, 70). Trimer binding was measured via depletion
of the unliganded trimer using UN-SCAN-IT densitometry software (Silk Sci-
entific) (19). Briefly, ID50s were calculated with reference to control lanes in each
gel, in which the density of a uncomplexed control trimer band is taken as 100%
and the density of a band that is fully liganded by a nAb (either b12, 2G12, or a
high concentration of plasma) is taken as 0%. Experiments were run a minimum
of 3 times to confirm the accuracy of ID50 estimates.
ELISA. JR-FL gp120 (a gift from Progenics Pharmaceuticals) was used to coat
wells of ELISA plates at 5 g/ml. Wells were blocked with 2% nonfat milk–
phosphate-buffered saline (PBS). For 2G12 competition ELISAs, MAb 2G12 or
plasma was added to wells at a fixed concentration or dilution. Graded dilutions
of biotinylated 2G12 were then overlaid, and alkaline phosphatase-conjugated
streptavidin was used to detect binding. The signal was developed with p-nitro-
phenol and was read at 405 nM.
RESULTS
Identification and classification of broadly neutralizing
plasma samples. Plasma samples from 308 chronically infected
subjects enrolled in CHAVI 001 or CHAVI 008 (17, 65, 76)
were assayed for neutralizing activity against 6 subtype B and
6 subtype C standard tier 2 reference strains of HIV-1 (55, 56).
The results revealed a wide range of geometric mean titers
(GMT) (Fig. 1). We categorized neutralization breadth into 3
“levels”: “level 1” plasma samples neutralized 8 out of 12
viruses with ID50s of 100; “level 2” plasma samples neutral-
ized 10 out of 12 viruses with ID50s of 100 and 8/12 viruses at
200; and “level 3” plasma samples neutralized 10/12 viruses
at 200 and 8/12 viruses at 300.
Ten percent of these plasma samples were classified as level
1, 2.5% as level 2, and 1% as level 3. We selected the 9 plasma
samples with the highest GMT (the top 3%), including all 3 of
the level 3 plasma samples (C1-0219, C1-0457, and C1-0763)
and 6 level 2 plasma samples, for mapping studies. These
subjects were from diverse geographic locations in Africa and
the United Kingdom and were infected with viruses derived
from subtypes A, B, C, or a recombinant A/C (Table 1). The
viral loads and CD4 counts at the time of sampling were typical
of chronic infections, with the exception of donor C1-0440,
who exhibited a low viral set point and a low CD4 count.
The plasma samples selected were further screened in neu-
tralization assays with a panel of 26 subtype A, B, and C tier 2
viruses (Fig. 2). Although all plasma samples neutralized each
clade, subtype preferences were observed, as evidenced by
differences in average titers. This observation reflects similar
observations from other cohorts (7, 36, 66). Plasma sample
C1-0219 had the strongest nAb response against several sub-
type-matched A viruses, while some non-subtype A-infected
subjects (C1-0440, C1-0269, C1-0534, and C8-0258) neutral-
ized clade A viruses relatively weakly. Furthermore, two sub-
type-matched combinations exhibited exceptionally high titers,
with ID50s of 10,000 (C1-0534 neutralization of CAP45.G3
and C1-0763 neutralization of Q23.17).
FIG. 1. Geometric mean titers (GMT) of nAb in plasma against a
12-virus panel. Plasma samples from 308 HIV-1-infected individuals
from the CHAVI 001 and CHAVI 008 cohorts were assayed against 12
reference strains of subtypes B and C. GMT are plotted on a log scale
(as the reciprocal plasma dilutions), and the 9 plasma samples (top
3%) with the highest titers are indicated by shading.
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To verify that plasma neutralization was IgG mediated, pu-
rified plasma IgG was tested in neutralization assays against a
panel of 12 tier 2 viruses, including 4 each of subtypes A, B,
and C. The neutralizing activity of the unfractionated plasma
samples corresponded to the purified IgG fraction of the
plasma, confirming that the neutralization was antibody medi-
ated (see Fig. S1A in the supplemental material). Since IgG1
was the predominant subclass in plasma, we examined a multi-
subtype breadth panel of HIV-1 gp140s for binding (see Fig.
S1B in the supplemental material). There was considerable
binding antibody breadth to clade A, B, and C HIV-1 Envs, as
indicated by the mean concentration (g/ml) of anti-Env IgG1
(with the strongest binding to subtype C Envs). The linear-
epitope specificities of the purified plasma IgG were tested by
using peptide arrays that spanned the entire gp160 of all major
subtypes and CRFs of HIV-1 (see Fig. S1C in the supplemental
material). Most plasma samples bound peptides in V3, the C5
immunodominant region (79), and the gp41 immunodominant
region, which are common specificities in chronic infection.
Other specificities included the V1V2 loop and the N terminus
and transmembrane regions of gp41. Thus, numerous multi-
clade binding specificities are present in broadly neutralizing
HIV-1-infected donor plasma samples.
We also asked whether neutralizing activity could be de-
tected in mucosal specimens from these donors. Epitope map-
ping of the purified mucosal IgG from a CVL sample from
subject C1-0536 is shown in Fig. S1D in the supplemental
material. Binding specificities of IgGs from CVL specimens
were generally parallel to the serum IgG response, with dis-
TABLE 1. Clinical data for the 9 HIV-1-infected individuals with
broadly cross-neutralizing plasma antibodies
Plasma
samplea











C1-0440 Malawi Female 22 6,402 96 C
C1-0269 Malawi Female 36 26,125 265 C
C1-0534 South Africa Female 29 140,601 348 C
C1-0175 Tanzania Female 24 108,353 877 A
C1-0219* Tanzania Female 48 20,888 309 A
C1-0457* Tanzania Female 33 36,955 442 C
C1-0536 Tanzania Female 33 50,926 299 A/C
C1-0763* Tanzania Female 31 390,322 570 A
C8-0258 United
Kingdom
Male 47 NAb 772 B
a Asterisks indicate level 3 neutralizers.
b NA, not available.
FIG. 2. ID50 titers of the 9 best neutralizers against a panel of 26 tier 2 viruses. Plasma neutralizing ID50 titers (reciprocal plasma dilutions)
against 6 subtype A viruses, 10 subtype B viruses, and 10 subtype C viruses are shown.
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proportionately lower responses to V2, C3, and C3/V4 (see
Fig. S1D). Although insufficient material was obtained to ex-
amine the neutralization breadth panel shown in Fig. 2, neu-
tralization of SF162 by purified IgG from a C1-0536 CVL
specimen was detected at a 50% effective concentration (EC50)
of 10.5 g/ml. This suggests that neutralizing IgG can exude
into genital secretions, although it is not clear how the titer
compares to that in plasma samples.
None of the plasma samples demonstrated any autoreactiv-
ity in the Athena Luminex assay (not shown). However, 7/9
subjects had anti-cardiolipin antibodies (not shown). This is
consistent with previous findings that anti-cardiolipin antibod-
ies correlate with neutralization breadth (41).
Cross-neutralizing activities targeting the gp41 MPER. We
first investigated whether nAbs directed to the gp41 MPER
were the basis for the broad neutralization seen in our 9
plasma samples. By use of a chimeric pseudovirus bearing an
HIV-2 Env engrafted with a clade B HIV-1 MPER region (3,
37), four plasma samples (C1-0269, C1-0534, C1-0175, and
C1-0536) exhibited nAb ID50 titers of approximately 1,000 or
greater, and another two (C1-0219 and C1-0763) had ID50
titers of 200 (Fig. 3A). All but one of these plasma samples
also neutralized a similar chimera containing a consensus clade
C MPER (not shown). An exception was plasma C1-0219,
which had an ID50 of 81 against the clade C MPER chimera,
approximately 3-fold lower than its titer against the clade B
chimera.
The same six plasma samples that exhibited neutralizing
activity against the MPER chimeras described above were also
positive in the post-CD4/CCR5 assay (Fig. 3B, where MPER
activity is shown as filled bars). This assay makes use of a
JR-FL SOS mutant virus where fusion ensues only after a
disulfide bond between gp120 and gp41 is broken by a reducing
agent, allowing partitioning and analysis of neutralization ac-
tivity that acts before or after receptor binding (1, 5, 21).
MPER nAbs have the ability to mediate neutralization after
the virus has engaged CD4 and CCR5 receptors. The propor-
tion of the total neutralizing activity contributed by MPER
FIG. 3. Plasma neutralization directed to the gp41 MPER. (A) Neutralizing activities against an HIV-2 chimera containing a full HIV-1 clade
B MPER graft are plotted as ID50 titers (reciprocal plasma dilutions). (B) Post-CD4/CCR5-engaged neutralization against a JR-FL SOS mutant
mediated by MPER nAbs, shown as filled bars overlaid on open bars that represent neutralization (ID50 titers [reciprocal plasma dilutions]) against
the same virus in the standard format (where the plasma and virus are incubated before receptor binding). Percentages of MPER-mediated
neutralization, calculated as (ID50 in the post-CD4/CCR5 format)/(ID50 in the standard format), are given below each stacked bar. (C) Breadth
of neutralization as probed by the effects of MPER peptide adsorptions on the neutralization of various pseudoviruses. Data are plotted as the
reduction in the percentage of neutralization from that with the no-peptide treatment. In controls, the peptide adsorbed all MAb 2F5 and 4E10
neutralization (not shown). N.D., not detected.
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nAbs can be determined by comparing the post-CD4/CCR5
titers with those obtained in the standard format, where the
SOS virus and nAbs are mixed before receptor binding (5, 21).
The four plasma samples with the highest MPER activity in the
chimera assays (C1-0269, C1-0534, C1-0175, and C1-0536)
contained gp41 MPER activity that constituted 17 to 30% of
the total neutralizing activity (Fig. 3B, % MPER). C1-0219 and
C1-0763 had lower titers of MPER nAbs, indicating that these
types of nAbs did not make a significant contribution to JR-FL
neutralization in these two plasma samples.
To determine whether MPER nAbs were responsible for
broad cross-neutralization, we performed depletion experi-
ments on the four plasma samples that appear to have the
highest proportion of MPER-neutralizing antibodies (Fig. 3B),
using an MPER peptide immobilized onto magnetic beads
(37). Depleted plasma samples were then tested for neutral-
ization of heterologous tier 2 viruses. Control experiments
showed that the peptide removed 95% of the neutralizing
activity of the MPER MAb 4E10 (not shown). For plasma
samples C1-0269, C1-0534, and C1-0536, MPER peptides re-
moved 90% of the neutralizing activity against the HIV-2/
HIV-1 MPER chimeric virus C1C (Fig. 3C). The MPER pep-
tide also removed 50% of the neutralizing activity against
most of a panel of 7 clade B and C reference viruses (Fig. 3C).
In contrast, the MPER peptide did not remove activity from
plasma C1-0175 against C1C and two heterologous isolates
that were neutralized by the nonadsorbed sample, although
MPER antibodies in this plasma sample were moderately re-
sponsible for Du156.12 neutralization. This result could reflect
either a low level of background activity against the scaffold
HIV-2 or a failure of the MPER peptide to fully mimic the
MPER epitope found on the virus particle. Neutralization of
the subtype A Q23.17 isolate was not significantly affected by
the depletion of MPER antibodies in any of the three samples.
Similarly, neutralization of Du156.12 by plasma C1-0534 and
neutralization of AC10.0.29 by plasma C1-0536 appeared not
to be mediated by MPER antibodies. All three viruses are
sensitive to MAb 4E10, so these observations are likely not
explained by any overt MPER resistance on the part of these
particular viruses. This suggests that these viruses are also
sensitive to another neutralizing specificity present in these
plasma samples.
Specificities of MPER-directed plasma neutralization. To
investigate the precise residues within the MPER recognized
by these plasma samples, we made use of chimeric viruses
where fragments of the HIV-1 MPER were engrafted into
HIV-2 7312A. Plasma samples C1-0269, C1-0534, and C1-0536
showed high neutralization titers against the C4, C4GW, and
C8 chimeras, which contain substitutions in the C-terminal
portions of the MPER, suggesting 4E10/Z13-like nAbs (Fig.
4A). All three plasma samples also showed low-level neutral-
ization of C6, which is the chimera neutralized only by MAb
4E10. To further pinpoint these specificities, we used a series
of MPER alanine mutant pseudoviruses in the clade C
COT6.15 Env background—a virus against which the MPER
peptide adsorbed most of the plasma neutralizing activity (Fig.
3C). This revealed a focus on residues F673 and D674 in the
C-terminal part of the MPER for all three plasma samples,
further suggesting 4E10/Z13-like epitopes (Fig. 4B). Plasma
sample C1-0269 was also sensitive to the W672A mutation,
which ablates MAb 4E10 neutralization (37). Plasma sample
C1-0536 and, to a lesser extent, C1-0269 were partially depen-
dent on W670 (Fig. 4B). The fact that the latter residue is
present in grafts C4GW and C8 but not in C4 might explain the
difference in the neutralization activity against these two chi-
meras by plasma C1-0536. Plasma samples C1-0269 and C1-
0536 were also sensitive to other C-terminal positions in the
MPER, notably L679A and W680A, the latter of which also
affects 4E10 neutralization (37). The binding of purified
plasma IgG from C1-0269 and C1-0534 to the MPER epitope,
as measured by surface plasmon resonance (expressed as the
dissociation constant [Kd]), was 112 nM and 268 nM, respec-
tively. These values are approximately 3.6- and 8.7-fold lower
than the Kd of the binding of MAb 4E10 to the MPER epitope
(100). No antibodies binding to the 2F5 epitope were detected,
indicating that the MPER responses in these plasma samples
were directed predominately to the 4E10 epitope.
We also examined neutralization using the JR-FL SOS mu-
tant virus in the post-CD4/CCR5 assay format. In this assay,
substitution of residues known to affect 2F5 (D664A) and 4E10
(W672A) ablated the neutralizing activities of 2F5 and 4E10,
respectively. As with the COT6.15 MPER mutants, there was
a focus on residues W672, F673, and D674 for neutralization in
all three plasma samples (Fig. 4C). The role of D674 was less
clear in this case, because the JRFL D674A mutant virus is less
sensitive to both 2F5 and 4E10 (not shown). This was not the
case for 4E10 neutralization of the COT6.15 D674A mutant
(37). Given that this epitope resides well outside the known
epitope for 2F5, we can infer that D674 mutations can result in
a globally resistant phenotype, characterized by a greater over-
all resistance to distal nAb specificities. This contrasts sharply
with the “globally sensitive” nature of many of the MPER
mutants (as evidenced by plasma ID50 titers below a 1:1 ratio
in Fig. 4B and C). Thus, the D674-dependent activity should be
viewed with caution, considering its ability to globally regulate
neutralization sensitivity. Nevertheless, the present data indi-
cate that the C-terminal portion of the MPER, in particular
W672, F673, and possibly D674, contributes to the broad neu-
tralization activities of these plasma samples, consistent with
4E10/Z13-like activity.
Cross-neutralizing activities targeting gp120 and the
CD4bs. gp120 monomer adsorption provides a way to partition
gp120-reactive nAbs from nAbs that recognize either quater-
nary epitopes or epitopes in gp41 (26, 57, 58, 89). ConC gp120-
depleted plasma was tested for neutralizing activity. In each
case, for the eight subjects tested, binding to the matched
ConC gp120 by ELISA was eliminated, confirming the efficacy
of adsorptions (not shown). Plasma sample C8-0258 was not
included in this analysis, because its ID50 against the ConC
virus was too low for any effects of depletion to be reliable.
Furthermore, another study describing plasma C8-0258 re-
ported that gp120 depletion did not affect neutralization
against the JR-FL isolate (76).
Using 50% depletion as the cutoff for significance, plasma
neutralization of the matched ConC pseudovirus was depleted
by ConC gp120 adsorption in all cases (Table 2). For four
plasma samples—C1-0175, C1-0219, C1-0457, and C1-0763—
neutralization of one or more other isolates was also depleted,
suggesting the presence of broad nAbs directed to the gp120
monomer. In contrast, the neutralizing activities of the remain-
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ing four plasma samples against other isolates were not effec-
tively depleted by gp120. These data suggest that anti-gp120
nAbs were partially responsible for neutralization breadth in
approximately 50% of the plasma samples tested, including all
the level 3 neutralizers.
To better understand the nature of the cross-neutralizing
gp120-specific nAbs, depletions were performed using a ConC
core gp120 lacking the V1V2 and V3 variable loops. In the case
of C1-0457, core gp120 was as efficient as gp120 at adsorbing
the ConC-neutralizing activity (Table 2). However, it was less
effective at depleting the neutralizing activity of C1-0219 and
almost completely ineffective at depleting neutralization in
plasma samples C1-0763 and C1-0175. This suggests that the
neutralizing activity of plasma C1-0457 targets an epitope in
the core of gp120, while the plasma from the other three
subjects depends on the variable loops to various extents.
We also investigated the ability of gp120 with point mutants
of key residues in the CD4bs (D368R) and CD4i (I420R)
epitopes to deplete neutralizing activity (57). The gp120
CD4bs (D368R) mutant was less efficient than wild-type gp120
at adsorbing the neutralizing activity of plasma C1-0219 against
several isolates, indicating that CD4bs nAbs were responsible
for some of the neutralization breadth in this plasma sample
(Table 2). However, the gp120 I420R mutant did not appre-
ciably affect gp120 adsorption of plasma C1-0219, and neither
of the mutant gp120s affected the adsorption of the other
plasma samples.
To further investigate the CD4bs nAbs in plasma sample
C1-0219, we examined the ability of a resurfaced gp120 core
protein (RSC3) to deplete neutralizing activity. RSC3 consists
of an SIV gp120 core engrafted with key residues important for
the binding of CD4bs antibodies (114), making it a highly
specific probe for binding only CD4bs nAbs. The RSC3 protein
depleted more than 40% of the neutralizing activity of plasma
FIG. 4. Fine specificity of MPER-neutralizing activities. Three plasma samples exhibiting significant MPER breadth were further analyzed to
determine the precise MPER epitopes. (A) Plasma samples were first assessed for neutralization of HIV-2 chimeras engrafted with various
segments of the HIV-1 MPER. The ID50 titers (reciprocal plasma dilutions) are given for plasma samples C1-0269, C1-0534, and C1-0536. The
concentrations (g/ml) equivalent to the IC50 are shown for the monoclonal antibodies (2F5, E10, Z13e1). (B) The activities against a series of
MPER mutants of the COT6.15 virus were assessed. The ratio of the neutralization ID50 against the parent virus to that against the mutant virus
is shown. (C) Neutralizing activities against a series of MPER mutants in the JR-FL SOS background were assessed using the post-CD4/CCR5
format (focused only on MPER activity). The ratio of the neutralization IC50 against the parent virus to that against the mutant virus is shown.
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C1-0219 against six viruses (Fig. 5A), consistent with the gp120
fractionation data (Table 2). In control experiments, RSC3
completely adsorbed the neutralization activity of VRC01
against six of seven primary viruses. A P363N mutant of RS3C
that affects the CD4 binding loop was unable to block VRC01
or plasma C1-0219 neutralization (114), confirming the speci-
ficity of the interference (Fig. 5A).
We next examined the binding of plasma C1-0219 to native
Env trimers in BN-PAGE shift assays and the effects of muta-
tions known to ablate the binding of CD4bs MAbs b12 and
VRC03. Plasma C1-0219 bound effectively to trimers, as did
CD4bs MAbs b12 and VRC03 (Fig. 5B) (7). D368R mutant
trimers completely knocked out the binding of both CD4bs
MAbs b12 and VRC03 and partially reduced the binding of
plasma C1-0219. This is consistent with the effect of the D368R
mutation on gp120 depletion (Table 2). No D368R-sensitive
binding activity was detected in any of the other plasma sam-
ples by BN-PAGE shifts (not shown). To further characterize
the specificity of plasma C1-0219, we examined the effects of a
mutation at residue W479, a known CD4 contact residue. This
mutant completely ablated VRC03 binding but had no effect
on b12, revealing a difference in the fine specificities of these
two MAbs. Plasma C1-0219 was unaffected by the W479G
mutant, suggesting that its CD4bs nAbs are more akin to b12
than to VRC03 (Fig. 5B).
Broadly neutralizing antibodies targeting HIV-1 gp120 vari-
able loops. We next investigated variable-loop-dependent neu-
tralizing activity by using panels of chimeric viruses (73), mak-
ing use of virus pairs that exhibit markedly different
sensitivities to neutralization by an individual plasma sample.
Seven of the nine plasma samples neutralized one of the pa-
rental pairs and were therefore tested against their chimeras in
which the variable loops (V1V2, C3-V4, V4, or V5) of the
sensitive virus were engrafted into the resistant Env back-
ground. Four plasma samples (C1-0440, C1-0219, C1-0536,
and C8-0258) showed no preferential activity against any of the
chimeras and thus were not investigated further. Plasma sam-
ples C1-0175 and C1-0534 neutralized three or all four of the
chimeras, respectively, suggesting that they target multiple or
complex epitopes (not shown). In contrast, plasma sample C1-
TABLE 2. Adsorption of neutralizing antibodies using recombinant envelope proteinsa
Plasma sample Virus ID50 withblank beads
gp120 gp120 core gp120 D368R gp120 I420R
ID50 % Ads ID50 % Ads ID50 % Ads ID50 % Ads
C1-0440 ConC 563 143 75 206 11 212 12
CAP45.G3 172 148 14
Du156.12 357 294 18
C1-0269 ConC 3,152 1,039 67 1,202 5 847 0
CAP45.G3 734 923 0
Du156.12 341 307 10
C1-0534 ConC 629 268 57 307 6 329 10
CAP45.G3 14,776 8,740 41
Du156.12 6,951 6,022 13
C1-0175 ConC 1,578 417 74 1,265 20 266 0 367 0
CAP45.G3 3,436 	60 98 	60 0 	60 0
Du156.12 320 239 25
C1-0219 ConC 2,711 880 68 1,652 39 1,508 23 1,253 14
CAP45.G3 3,713 988 73 1,939 26 1,772 21
Du156.12 1,013 480 53 931 45 502 2
SC422661 338 	60 82 263 60 124 19
C1-0457 ConC 2,428 	60 95 159 93 324 11 	60 0
CAP45.G3 4,006 	60 99 	60 0 	60 0
Du156.12 1,129 154 86 242 8 120 3
SC422661 145 	60 59 	60 0 	60 0
C1-0536 ConC 489 131 73 120 0 187 11
CAP45.G3 2,126 3,554 0
Du156.12 913 764 16
C1-0763 ConC 22,392 5,608 75 19,699 12 6,606 4 5,671 0
CAP45.G3 13,037 1,523 88 2,467 7 2,834 10
Du156.12 1,578 487 69 612 8 713 14
a Plasma fractionation was carried out with monomeric gp120 and gp120 mutants. Plasma samples were adsorbed with wild-type ConC gp120-coated beads, and the
neutralizing ID50s (reciprocal plasma dilution) against various pseudoviruses were determined. Blank beads were used as a control. The percentage of neutralization
(% Ads) directed to gp120 was calculated as the reduction in the ID50 by adsorption with wild-type gp120 from the ID50 with blank beads 
(ID50 with blank beads 
ID50 with wild-type gp120)/(ID50 with blank beads). A similar procedure was used to evaluate the adsorptive abilities of a gp120 core lacking the V1V2 and V3 loops,
a gp120 variant containing a mutation in the CD4 binding site (D368R), and a gp120 variant containing a mutation affecting the detection of CD4i epitope-directed
antibodies (I420R). For these, CHAVI plasma sample C8-0258 was not tested, because its ID50 titer against the ConC virus was too low. The percentage of
neutralization directed to each mutant was calculated as 
(ID50 with the gp120 variant  ID50 with wild-type gp120)/(ID50 with blank beads). Values equal to or greater
than 50% for wild-type gp120, and values equal to or greater than 20% for the mutants, are shown in boldface. In cases where no neutralization was observed at the
lowest dilution (1:60), a value of 	60 is given.
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0763 neutralized only the V1V2 loop-engrafted chimeras made
between the sensitive CAP45 and the resistant CAP84 virus
(Fig. 6A). This result was replicated with a second virus pair
(not shown), confirming that plasma C1-0763 recognized a
V1V2 loop-dependent epitope.
To determine whether the anti-V1V2 nAbs in C1-0763 cor-
FIG. 5. Detection of CD4bs nAbs. (A) Effects of interference by resurfaced cores RSC3 and dRSC3 P363N on the neutralization of various
viruses by plasma C1-0219 or MAb VRC01. (B) Binding of plasma C1-0219 and MAbs b12 and VRC03 to native JR-FL SOS Env trimers as
determined by BN-PAGE and the effects of mutations D368R and W479G, which affect the CD4bs. Trimer binding is assayed by a loss in trimer
staining density (shown as bars), since trimers are complexed with nAbs.
FIG. 6. Detection of V1V2 nAb activity in plasma sample C1-0763. (A) Neutralization by plasma C1-0763 (ID50 titer [reciprocal plasma dilution])
of the CAP45 virus and the CAP45 V1V2 engrafted into the background of the less-sensitive virus CAP84. (B) The eluate from plasma C1-0763
adsorption on gp120 beads mediates V1V2-directed neutralization, as indicated by neutralization of the chimeric CAP84 virus containing the CAP45
V1V2 loop. Parental viruses CAP45 and CAP84 were used as positive and negative controls, respectively. (C) Effects of mutations at position K169 in
the V2 loop of the CAP45 virus on neutralization by plasma C1-0763. Each bar represents the ID50 titer (reciprocal plasma dilution) obtained with a
wild-type (WT) or mutant CAP45 virus. (D) Effect of K169E mutation on the ability of monomeric CAP45 gp120 to adsorb plasma neutralization against
the CAP45 virus. Each bar represents the ID50 titer obtained with the plasma samples after adsorption with blank beads, wild-type gp120, or gp120 K169E.
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responded to those that were depleted by the gp120 monomer,
we assayed the antibodies eluted from the gp120-coated beads
against the sensitive and resistant virus pair as well as the
V1V2 chimera. We found that the CAP45 virus and the chi-
mera containing the CAP45 V1V2 region were both sensitive
to the gp120 eluate, while the CAP84 virus was resistant (Fig.
6B). Furthermore, using V2 loop point mutants, we identified
residue K169 as crucial for neutralization, with both 169V and
169E having dramatic effects (Fig. 6C). Adsorption experi-
ments using a CAP45 gp120 variant with a K169E mutation
completely ablated the depleting abilities of gp120 for this
plasma (Fig. 6D). This indicates that the V2-directed gp120-
adsorbable neutralizing antibodies in plasma C1-0763 depend
on residue K169 in the V2 loop. Thus, while the antibodies in
plasma C1-0763 targeted a region similar to that targeted by
MAbs PG9 and PG16, they were unlike PG9 and PG16, whose
V2 activity depends on a quaternary structure and is therefore
not absorbable by gp120.
Detection of PG9/PG16-like neutralizing activity. The glycan
at position 160 in the V2 loop is a critical part of the epitope
of MAbs PG9 and PG16, and viruses with a mutation at this
site are often used to define this specificity (although differ-
ences between isolates have been noted) (112). To investigate
this, we examined N160-dependent activity in four different
viral Env backgrounds. As expected, MAbs PG9 and PG16
were unable to neutralize the N160 mutants of any of the
ConC, Q23.17, CAP45, and UG037.8 Envs (Fig. 7). Using this
approach, we found that the neutralizing activity in two of the
nine plasma samples was sensitive to a mutation at this posi-
tion. The neutralization titers of plasma samples C1-0219 and
C1-0763 were substantially reduced by N160A mutations in the
ConC and CAP45 viruses and by an N160K mutation in the
Q23.17 virus (Fig. 7). None of the other plasma samples
showed a significant effect (Fig. 7). The UG037.8 virus N160K
mutant did not reveal activity in any of the plasma samples,
underscoring the various results seen with different isolates.
FIG. 7. Mapping of neutralizing activity sensitive to the replacement of residue N160. The neutralization activities of each of our plasma
samples and MAbs PG9 and PG16 were assayed against four viruses (ConC, Q23.17, CAP45, and UG037.8) bearing mutations at residue N160
in the gp120 V2 loop. Data are expressed as the percentage of the reduction in titer relative to the neutralization of the unmutated parent virus.
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To further determine whether activities in plasma samples
C1-0219 and C1-0763 shared residues with PG9 and PG16, we
used a series of V2 and V3 point mutants in two different Env
backgrounds. N160A and K169E mutations in both Env back-
grounds had profound effects on PG9 and PG16, which were
also affected, albeit to a lesser degree, by V127A, F159A,
K171A, K171E, and I181A, depending on the background Env
(Fig. 8). N160A and K169E had similar profound effects on
both plasma samples in the CAP45 background, where C1-
0219 was also affected by K171E, while C1-0763 was also af-
fected by L165A.
In the ConC background, both plasma samples were affected
by the N160A mutant, but very little effect was seen with the
K169E mutant. In addition, mutations at residues 159 and 181
reduced the neutralization titers of plasma samples C1-0219
and C1-0763 at least 3-fold (Fig. 8). Plasma C1-0219 neutral-
ization was also reduced by a V127 mutant in the V1 loop,
while that of plasma C1-0763 was also reduced by an R132A
mutation in the V1 loop and by R166A and K168A mutants in
the V2 loop. The latter two sites distinguished C1-0763 from
PG9 and PG16.
In the JR-FL background, the R166A mutant knocked down
plasma C1-0219 (see Fig. S3 in the supplemental material),
indicating that the precise substitutions affecting C1-0219 neu-
tralization in each Env background differed. Collectively, these
findings suggest that plasma C1-0219 may contain a swarm of
V2 nAbs that recognize slightly different epitopes on the V2
loop, depending on the Env isolate. Alternatively, these knock-
down effects could be steric and could actually affect binding to
a neighboring site. In addition, the presence of CD4bs neu-
tralization activity in this plasma sample may significantly in-
hibit attempts to accurately determine V2 knockout mutants,
whose effects may be camouflaged by the retention of back-
ground CD4bs activity.
In contrast to the knockdown effects on neutralization of
ConC by plasma C1-0763 (see Fig. S2 in the supplemental
material), this plasma sample was not affected by V2 mutations
in the JR-FL background (see Fig. S3 in the supplemental
material). These differential effects could be explained by a
failure of the V2 activity to cross-react with JR-FL Env and/or
the presence of additional nAb activities in this plasma sample
that mask the effect of the V2 antibodies against the JR-FL
virus. The neutralization titers of plasma C1-0763 were signif-
icantly lower against JR-FL (ID50, 325) than against ConC
(ID50, 10,000), suggesting that the potent V2 loop-directed
activity may simply not cross-react with the JR-FL isolate.
The use of mutants in the JR-FL background also revealed
activity in plasma C1-0457 that was not detected against either
ConC or CAP45. This affected residues 165, 166, and 167 in
the V2 loop. One possibility is that this neutralizing activity is
restricted in breadth, such that it does not cross-react with
ConC or CAP45. Alternatively (or additionally), the effects of
the V2 activity may be masked by other neutralizing specific-
ities effective against the ConC Env but not against JR-FL. In
support of the latter possibility, plasma C1-0457 neutralized
the ConC virus with an approximately 10-fold higher titer.
FIG. 8. Effects of mutations in V1V2 and V3 on neutralization by plasma samples C1-0219 and C1-0763. The neutralizing activities of plasma
samples C1-0219 and C1-0763 and of MAbs PG9 and PG16 were tested against single point mutants with mutations in the V2 region of CAP45.G3
(A) and the V1V2 and V3 regions of ConC (B). Data are expressed as the ratio of the ID50 against the parent virus to that against the mutant
virus. Mutations that resulted in a significant fold change are highlighted in colors shading from yellow (2- to 5-fold) to red (100-fold). Amino
acid numbering is based on the sequence of HXB2.
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We also examined V3 mutations (see Fig. S3 in the supple-
mental material), because these are also components of the
PG9/PG16 epitope. Neutralization by plasma C1-0219 was af-
fected by the R304A mutation in the N-terminal base of the V3
loop in JR-FL and by the K305A, I309A, and Y318A muta-
tions in ConC. We found no evidence for competition of
JR-FL neutralization using V3 peptides (experiments were
performed as described previously [7]), suggesting that this V3
reactivity does not depend on linear V3 sequences. Plasma
C1-0763 was sensitive to mutations in and around the C-ter-
minal portion of the V3 loop, including E320A, G323C, and
D324A in JR-FL and K305A, I309A, and F317A in ConC.
Given that no evidence was found for V2 knockouts in the
JR-FL background, it is possible that this V3 dependency is a
distinct neutralizing specificity and is not linked to V2. Overall,
the effects in V3 were minor compared to those in V2, with
some overlap with the sites targeted by MAbs PG9 and PG16.
Cross-neutralizing antibodies targeting glycans. Glycans on
the gp120 outer domain are also the target of nAbs, as typified
by MAb 2G12. Thus, we explored mutants designed to knock
out gp120 glycans. N332A and N339A mutations of JR-FL
knocked down plasma samples C1-0763 and C1-0175, respec-
tively (see Fig. S3 in the supplemental material). In the ConC
background, it was difficult to determine the effect of the
N332A mutation, because in this Env background the mutant
was globally sensitive (not shown). We therefore investigated
the effects of N332A mutants in four other virus Envs (Fig.
9A). This revealed that N332A knocked out C1-0763 neutral-
ization of the clade B isolates JR-FL and TRO.11, but not the
clade A (Q23.17) or C (Du156.12) viruses. The TRO.11
N332A mutant also became more resistant to neutralization by
plasma samples C1-0440 and C1-0457. Plasma C1-0440 was
also sensitive to the N332A mutant in the Q23.13 background.
This suggested that at least three of the nine plasma samples
contained broadly neutralizing antibodies that relied on the
N332 residue.
Residue N332 is a central contact of the MAb 2G12 epitope
(14, 87, 94). We therefore tested for 2G12 competition for
binding to JR-FL gp120 by ELISA. Plasma C1-0763 was able
to partially block the binding of biotinylated 2G12, whereas
plasma C1-0219 had no effect (Fig. 9B). As expected, unla-
beled 2G12 was able to compete biotinylated 2G12 effectively.
This suggests that the N332A-sensitive activity in plasma C1-
0763 overlapped the 2G12 epitope. It is unlikely to be exactly
similar to 2G12, because it was not dependent on N295, which
is a major core contact for MAb 2G12, along with N339, N386,
and N392 (87).
DISCUSSION
A key question regarding broad plasma neutralization of
HIV-1 is whether it is typically mediated by one (or a very few)
broad and potent antibody or by the sum of the activities of a
large number of narrowly focused neutralizing specificities.
Studies exemplifying both of these scenarios have been re-
ported (4, 95, 112). The present study represents an extensive
collaborative effort of multiple laboratories employing a vari-
ety of mapping tools and provides evidence that two or more
distinct antibody specificities can sometimes mediate breadth
in a single subject (summarized in Fig. 10). Interestingly,
bnAbs with the greatest magnitude and breadth targeted
gp120, while those with less breadth recognized the MPER,
and these two general specificities were largely mutually exclu-
sive. In at least one case (C1-0219), two distinct bnAb speci-
ficities against gp120 were identified, one resembling PG9/
PG16 and the other directed against the CD4bs. The fact that
both specificities have been isolated as broadly neutralizing
FIG. 9. Sensitivity of plasma neutralization to N332A mutation and
overlap with the MAb 2G12 epitope. (A) The effects of N332A mu-
tation in the contexts of various viruses on plasma neutralization were
determined. (B) Abilities of plasma samples to compete with MAb
2G12 for gp120 binding. Plasma samples at a fixed dilution of 1:50 or
2G12 at a fixed concentration of 10 g/ml was used to compete against
biotinylated 2G12, which was titrated against the plasma or 2G12-
blocked immobilized JR-FL gp120.
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MAbs from this subject (10; J. R. Mascola, unpublished data)
validates the presence of multiple plasma antibody specificities
in a single individual, as well as the utility of mapping efforts to
identify interesting epitopes for further study, including the
isolation of novel broadly neutralizing MAbs. The presence of
multiple broadly neutralizing antibodies circulating in plasma
suggests that vaccines could, in theory, be designed to stimu-
late the immune response to productively develop multiple
neutralizing antibody specificities that confer breadth.
We made use of a number of different methods to map the
antibody specificities mediating broad neutralization in plasma
from 9 chronically infected, antiretroviral-naïve subjects se-
lected from a cohort of 308 patients infected mostly with sub-
types A and C. The results of three different assays confirmed
the presence of anti-CD4bs antibodies in plasma C1-0219. This
included the use of ConC recombinant gp120 with a mutation
at position 368 in the CD4bs that failed to deplete neutralizing
activity, as well as the use of a YU2 resurfaced core protein
that specifically binds CD4bs antibodies. A third method mea-
sured blue native gel band shifts and showed that C1-0219
efficiently shifted a JR-FL trimeric Env; this shift was lost when
a protein containing the position 368 mutation was used, as
with the prototype CD4bs MAbs, b12 and VRC03. None of the
other 8 samples contained anti-CD4bs antibodies as deter-
mined by these methods, suggesting that broadly neutralizing
CD4bs antibodies are induced relatively infrequently.
The presence of anti-MPER Abs was confirmed in at least 3
of the plasma samples in multiple assays. An HIV-2/HIV-1
MPER chimera detected high activity in 6 plasma samples, 3 of
which were shown to mediate cross-neutralization via this spec-
ificity. These Abs were also detected in a fusion assay that
showed that while they were a major component, they in fact
represented only one-third to one-quarter of the total plasma
neutralizing activity. A summary of the mapping data is shown
in Fig. 10; it indicates that 8 of the 9 plasma samples contained
at least 2 to 3 specificities that could be identified. However, in
all cases, we could not account for all activity, suggesting that
multiple nAb specificities of less breadth may also contribute
to neutralizing activity.
Several other observations exemplify the complex nature of
these plasma samples. (i) ConC gp120 adsorbed neutralizing
activity against the matched isolate in all cases tested, yet only
in 3 plasma samples was this truly cross-neutralizing. (ii)
Plasma C1-0457 was effectively adsorbed using ConC gp120,
which lacked a V2 loop, yet neutralization of JR-FL was
knocked out by V2 loop mutations. (iii) Plasma C1-0763 was
affected by mutants in V2 in a clade C background, but by V3
mutations and the N332A mutation on JR-FL. Part of this
disparity is likely due to the backbone used to make these
mutants, as clearly shown with N160 and N332 (Fig. 7 and 9),
and thus, it is important to verify such findings in more than
one background. A further caveat is that many Env point
mutants are globally sensitive to distal specificities (Fig. 8 and
9). When this occurs, it suggests that the mutated residue is not
FIG. 10. Summary of broadly neutralizing antibody targets. The neutralizing epitopes targeted by the plasma antibodies from the nine subjects
studied here can be described in six broad categories: MPER, CD4bs and CD4i, gp120 core, V2 variable loop, PG9/PG16-like, and 2G12-like. The
methods utilized to define the specificities of neutralizing antibodies are indicated (along with the relevant figure and table numbers). Different
colors in the shaded boxes indicate the presence of neutralizing antibody specificities circulating in each subject’s plasma.
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entirely solvent exposed and may be involved in trimer pack-
ing. This is in fact a very common phenomenon that has also
been reported in several recent studies (9, 74, 78, 100, 101,
112). Our observation that a relatively larger fraction of gp41
MPER mutants than of gp120 mutants cause global sensitivity
(compare Fig. 5B and C to Fig. 8 and 9) is consistent with the
idea that the MPER is partially sequestered and is involved in
protein-protein or membrane associations, so that substitu-
tions often lead to global effects on folding. In contrast, most of
our gp120 mutants are likely to be surface exposed and there-
fore to minimally affect trimer packing. A previous bioinfor-
matics study identified a series of residues that partitioned with
broad neutralization, i.e., polymorphisms at these positions
were associated with the presence or absence of broad neu-
tralization (34). Several of these residues corresponded to the
bridging sheet and coreceptor binding site and were found to
cause global sensitivity when mutated. Therefore, it is possible
that the development of broad neutralization might relate to
trimer “compactness.”
In contrast to the findings of our study, Walker and col-
leagues found that the neutralization activity in 19 elite plasma
samples was most often dominated by a single specificity and
that MPER activity was minimal (112). It is not clear why the
findings were different in the two studies. The Walker study
used plasma from 14 subjects who ranked among the top 1% of
neutralizers and from 5 additional subjects who ranked among
the top 5% in a cohort of 1,798 subjects in International AIDS
Vaccine Initiative (IAVI) protocol G (112). We used plasma
from 9 subjects who ranked in the top 3% of a cohort of 308
subjects, including 3 subjects who were in the top 1%. The two
studies also used different viruses and assay techniques. Previ-
ous studies have pointed out that detection of antibodies tar-
geted to gp41 can depend on the target cells used in the assay.
MAb 4E10 neutralization was found to be more sensitive in the
TZM-bl assay (8), whereas other neutralizing antibodies di-
rected to gp41 were better detected in the PBMC-based assay
(30). These differences highlight the importance of examining
multiple cohorts and using different approaches to capture the
full spectrum of activities and to identify all possible targets on
HIV-1 Env.
Various studies have hinted at the presence of unusual neu-
tralizing specificities, some of which may be entirely novel. One
report suggested that Abs overlapping the CCR5 binding site
and sensitive to an I420R mutation in the bridging sheet can
mediate broad neutralization (58). Although there is scant
evidence for 2G12-like bnAbs from most mapping studies to
date (4), recent studies revealed that a gp120 N332 mutation
can sometimes ablate plasma neutralization, suggesting bnAb
specificities that overlap the 2G12 epitope and may reside on
the outer domain of gp120 (36, 38, 76, 109, 110).
In a recent review of mapping efforts to date, CD4bs activity
accounted for a substantial proportion of the neutralizing ac-
tivity in 12 of 43 plasma samples, whereas substantial MPER
activity was present in 3 (4). Importantly, more than 50% of
bnAb activity in 28 of the plasma samples could not be
mapped. In approximately 50% of cases, gp120 failed to adsorb
neutralizing activity (36, 37, 41). This suggests that much of the
unmapped activity may target quaternary, trimer-dependent
epitopes (35). Indeed, two recent studies (72, 112) have re-
ported nAbs that recognize epitopes similar but not identical
to those of MAbs PG9 and PG16. The results of another recent
study suggested that the early nAbs preferentially target the
CD4bs, while more broadly neutralizing Abs cannot be ad-
sorbed by gp120 (i.e., PG-like or possibly MPER) and appear
to be associated with CD4 T cell activation (66) and CD4 T cell
decline upon infection (36).
Although MPER nAbs have been detected frequently in
multiple studies, they only rarely exhibit neutralization breadth
(4, 7, 37, 39, 41, 101). This may be because MPER nAbs tend
to lack the potency of nAbs that target gp120. Thus, MPER
neutralization may feature more prominently in plasma sam-
ples that exhibit somewhat weaker overall neutralization titers.
It may therefore not be a coincidence that MPER accounted
for little or none of the neutralization in our level 3 neutral-
izers (C1-0219, C1-0763, and C1-0457; top 1%) (findings sim-
ilar to those of the IAVI study) but featured more prominently
in at least 3 of our 6 level 2 neutralizers. The epitope of the
MPER nAbs in these plasma samples resembled that of MAb
4E10, consistent with most previous studies (4). Despite its
breadth, the lack of potency of 4E10 could explain why similar
nAbs do not contribute significantly in most broadly neutral-
izing plasma samples. One possible reason why MPER nAbs
are reported so commonly in mapping studies may simply
relate to the fact that this is the only epitope to which we can
measure neutralization directly, without the contribution of
other nAbs that are present. With other epitopes, in contrast,
mutant viruses, adsorption, and other techniques are needed in
order to identify nAb activity against discontinuous conforma-
tional epitopes. Thus, we can detect exceedingly low titers of
MPER nAbs, whereas at least half of the total neutralization
activity must be affected to allow reliable measurement of
other specificities using current technologies. In the case of
plasma samples C1-0269, C1-0534, and C1-0536, this observa-
tion was consistent with MPER nAbs playing a significant role
in the neutralization of most, but not all, viruses (Fig. 3C).
Thus, the weak MPER activity detected in plasma samples
C1-0175, C1-0219, and C1-0763 (Fig. 3A and B) is overshad-
owed by other nAbs targeted to gp120, as was suggested by the
inability of MPER peptides to deplete neutralization of these
plasma samples against most isolates tested (Fig. 3C and data
not shown). An exception is C1-0175 neutralization of the
Du156.12 isolate, which was largely explained by MPER nAbs
(Fig. 3C). Thus, we can infer that other specificities contribute
to the breadth of all 9 plasma samples, with MPER nAbs
playing a supporting role in some, but not all, cases and that, in
many cases, breadth is achieved by multiple specificities. Since
we have identified several subjects whose samples naturally
elicited MPER-neutralizing antibodies with some breadth,
eliciting neutralizing MPER antibodies is a reasonable goal for
HIV-1 vaccine design in concert with the elicitation of multiple
broadly neutralizing specificities.
A substantial portion of ConC-neutralizing activity in the
nine plasma samples was adsorbed by gp120 (Table 2), but only
in the three level 3 neutralizers was cross-neutralizing activity
against other viruses adsorbed. In the case of level 3 plasma
sample C1-0763, V2-reactive activity was adsorbed by gp120,
and the precise residues in V2 were mapped and shown to
involve N160 and K169 (Fig. 6), which are also required by
PG9 and PG16. Plasma C1-0219 was also found to contain V2
loop-reactive activity. This plasma sample was also sensitive to
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the N160 and K169 mutations, suggesting epitopes related to
those of the PG MAbs. The frequency of this specificity is
consistent with that in the IAVI study, in which 5 of 19 plasma
samples were N160 dependent. It may not be a coincidence
that these two plasma samples were derived from clade A
infections, as were the PG MAbs, raising the possibility that
such specificities evolve more often during clade A infections.
The potency of the V2 specificities is exemplified by the dra-
matic effects of N160 mutants on neutralization of the Q23.17
and CAP45 viruses by plasma samples C1-0219 and C1-0763.
In each case, this V2 activity accounts for most, if not all, of the
neutralizing activity that imparts extremely high ID50 titers,
close to 10,000 (Fig. 2). It will be worthwhile to characterize
this powerful activity more precisely in the future, especially if
it cross-reacts with viruses from other clades.
Two recent plasma mapping studies further suggest that
“PG-like” plasma nAbs may not precisely replicate the activi-
ties of the prototype MAbs (72, 112). Similarly, 2909-like qua-
ternary nAbs isolated from SHIV-infected macaques exhibited
specificities slightly different from that of the 2909 prototype
(84). Taken together, these findings suggest that V2 or “PG-
like” nAbs found in broad plasma samples can have various
V-loop residue dependencies that may overlap but do not
necessarily precisely replicate the known specificities. This is
perhaps not surprising in view of the substantial variability of
the V2 loop. The V2 dependencies of our three V2 specificity-
containing plasma samples on ConC and JR-FL backgrounds
are each substantially different, illustrating this point. One of
these three plasma samples (C1-0457) was susceptible to a
mutation at I165 of the JR-FL V2 loop (see Fig. S3 in the
supplemental material) that was previously found to be a target
of 5 plasma samples in the IAVI study, but distinct from
PG-like nAbs, which are not sensitive to this mutation (112).
This residue has been shown to regulate neutralization by
trimer-specific MAbs 2909, 2.3E, and 2.2G (35, 84). Although
these nAbs are strain specific, they recognize quaternary
epitopes involving the V2 and V3 loops.
Three plasma samples (C1-0440, C1-0457, and C1-0763)
were sensitive to the glycan at N332, depending on the virus
strain. In at least four previous plasma mapping studies, this
sensitivity has also been observed (76, 36, 112). One group has
now isolated broadly neutralizing MAbs with this specificity via
high-throughput screening of donor B cells (110). In our study,
the neutralizing activity of at least one of our plasma samples,
C1-0763, was broadly adsorbed by gp120 (Table 2), as observed
for most of the previously reported N332-sensitive plasma sam-
ples (76, 112). However, there is a complexity of specificities in
plasma C1-0763 (V2 linear, V3, MPER, N332A). Interestingly,
unlike the N332A-dependent activity observed previously
(112), plasma C1-0763 partially competed with biotinylated
2G12 for gp120 binding (Fig. 9B). It is worth noting that the
N332 and N339 glycans are part of the alpha-2 helix, a known
neutralizing epitope for clade C plasma samples (71, 85). Thus,
it appears possible that, as with the V2 activity, broad neutral-
izing responses can ultimately develop from initially highly
type specific responses, with time and sustained virus replica-
tion. Thus, N332A affects the neutralization by C1-0763 of
clade B viruses (JR-FL and TRO.11) but not of the other
viruses. This may be because this plasma is able to neutralize
these other viruses via the V2 loop specificities discussed
above, which may not cross-react with the clade B viruses.
C1-0219 is a clear example of multiple specificities in plasma
mediating breadth. This plasma sample contained prominent
neutralization activity directed to both the CD4bs and the
V1V2 loops. Despite the breadth of the CD4bs nAbs, this
activity did not explain all of the neutralizing activity against
any of the isolates tested (Table 2). Indeed, the relative con-
tribution of the CD4bs nAbs to the neutralization of a given
virus appeared to depend on the overall sensitivity of the virus
to the plasma sample. Thus, when C1-0219 exhibited modest
neutralization titers (e.g., Du156.12 and SC422661.8), CD4bs
nAbs played a major role (Table 2; Fig. 5A). However, when
C1-0219 exhibited high neutralization titers, the contribution
of CD4bs nAbs was less significant. Thus, while the partial
adsorption seen with gp120 in this plasma was likely due to the
D368R-sensitive CD4bs nAbs, the remaining activity was de-
pendent on quaternary structures similar to those of the PG
MAbs, which were sensitive to N160. Indeed, MAbs to both
targets have now been isolated from this individual. These
include antibodies CH01 to CH04, which map to the V2 region
and are trimer dependent but are distinct from PG9/P16 (10),
and three potent anti-CD4bs MAbs (113a) isolated using the
RSC3 protein, as was done for VRC01 (114). Interestingly,
isolates, such as CAP45.G3, that were only weakly neutralized
by plasma CD4bs antibodies (Table 2) were very sensitive to
the anti-V2 MAbs CH01 to CH04 (10), accounting for the
potency of the plasma against this virus. Similarly, Du156.12
was sensitive to MAbs CH01 to -04 but not to the new anti-
CD4bs MAbs. In contrast, isolates such as ZM109.4 were sen-
sitive only to the anti-CD4bs MAbs, not to the anti-V2 MAbs
isolated from C1-0219. These data confirm, through the use of
monoclonal agents, that neutralization breadth can be medi-
ated by two distinct antibody specificities in a single subject.
We were not able to determine the specificity of the cross-
neutralizing activity in all the plasma samples. A case in point
is that plasma C8-0258 was not significantly mapped by any
method. This could be due to complexity of nAb specificities in
this plasma or to our incomplete array of mapping tools. It is
noteworthy that this individual was the only one infected with
a clade B virus, and while the sample did show cross-clade
neutralization (Fig. 2), it was weak against clade A. It is pos-
sible that breadth in this individual may be due to multiple
narrow specificities or that we have overlooked CD4bs nAbs
that are not D368R dependent (95), such as MAb HJ16 (18).
Additionally, our study focuses on IgG-mediated neutralizing
activities in the plasma and not on other antibody isotypes. We
have found that purified IgA from the plasma of HIV-1
subjects can neutralize (data not shown), which indicates that
IgA, in addition to IgG, may be responsible for some aspects of
virus inhibition in both broad neutralizers and other HIV-1-
infected subjects.
Overall, our results support the idea that multiple distinct
bnAb responses can evolve in some people. In cases where
neutralization appears to be more clonal, this may not rule out
multiple specificities; it means only that one specificity domi-
nates neutralization. Only with time do bnAb responses finally
develop in some subjects, and there is evidence that ongoing
viral replication contributes to the development of these
bnAbs (36, 66, 89). What remains unknown is why only certain
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individuals are capable of mounting a bnAb response. Is there
something unique about the virus and the antigenic structure
of its Env that favors antibody responses to conserved
epitopes? The fact that the epitopes are present on most vi-
ruses would argue against this, unless regions outside the
epitope can control immunogenicity. Another possible expla-
nation is that the response is differentially controlled by host
genetics. In this regard, our results suggest that the B cell
response in certain individuals is privileged to target multiple
unrelated bnAb epitopes that most likely require different IgG
heavy and light chain gene usage. Identification of the biologic
process governing these selective responses could yield valu-
able insights for vaccine design.
The significance of our findings also relates to the discovery
of new neutralizing MAbs. In some instances, knowledge of the
predominant nAb specificities may directly assist in MAb iso-
lation. For example, in the present study, B cell receptor li-
gands consisting of parent CAP45.G3 gp120 and its K169E
mutant might function effectively as positive and negative re-
agents for the selection of V2-neutralizing MAbs from the B
cells of donor C1-0763 in a flow cytometry screening protocol
similar to that reported recently (38, 114). Such rational ap-
proaches may accelerate the isolation of new bnMAbs, provid-
ing new tools for vaccine design.
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